Xeomin, Botox show similar efficacy for treatment of glabellar lines in multicenter comparison

Merz Aesthetics has announced positive results from a post-market, parallel-group clinical trial comparing Xeomin with Botox for the treatment of glabellar facial lines.

The primary efficacy endpoint, which was defined as one point or greater improvement from baseline on the Facial Wrinkle Scale at maximum frown, was met 1 month after a single treatment. In addition, similar results were found between the Xeomin (incobutlinumtoxinA) and Botox (onabotulinumtoxinA, Allergan) treatment groups at all other post-treatment time points (2, 3 and 4 months), according to a company press release.

"Leading investigators conducted a randomized, blinded clinical trial directly comparing the two leading FDA approved neurotoxins, Botox and Xeomin, in on-label use for glabellar lines. In addition, non-treating investigators (dermatology and plastic surgery thought leaders) judged photographic results in a blinded review, acting as impartial referees. The results speak for themselves: no significant differences in efficacy, potency or safety, " Philip Werschler, MD, FAAD, FAACS, told Healio.com/Aesthetics.

Headache, infection and facial asymmetry were the most commonly reported adverse events.

"The results of this clinical trial offer evidence that there are multiple effective options for injectors and patients seeking a neurotoxin for aesthetic use," co-lead author, Fredric Brandt, MD, said in the press release.

According to the company, other head-to-head comparison studies have demonstrated that incobutlinumtoxinA and onabotulinumtoxinA have comparable safety and efficacy for both cosmetic and therapeutic uses, and the findings from this trial are consistent with previous studies.

"Given the fact that this is the first large, multicenter, parallel-group study to investigate the comparable efficacy of Xeomin to Botox in the treatment of glabellar frown lines, these study results have meaningful implications for patients and physicians alike," Michael Gold, MD, FAAD, a key researcher in the study, said in the release.

Reference: www.merzusa.com.